Aspinall is a healthcare industry leader and pioneer committed to active civic involvement. She is Partner at Illumina Ventures, an independent venture firm focused on genomics and precision diagnostics. Aspinall is Editor of Senstive & Specific: The Testing Newsletter and Diagnostics Year in Review. She was previously Co-Founder and Managing Director of BlueStone Venture Partners. Aspinall is a member of the Board of Directors of OraSure Technologies(OSUR) and Blue Cross Blue Shield Arizona. Aspinall is certified in Cybersecurity Oversight from Carnegie Mellon University and the National Association of Corporate Directors.
Previously, as President and CEO of Ventana Medical Systems, a billion-dollar division of The Roche Group, (now Roche Tissue Diagnostics) Aspinall led her world-class team to new heights including more than two dozen major instrument and assay launches as well as global leadership in companion diagnostics.
Aspinall spent 13 years at Genzyme Corporation where she served as President of Genzyme Genetics and Genzyme Pharmaceuticals. Genzyme Genetics was a leading provider of diagnostic testing and genetic counseling in the oncology and reproductive markets. Aspinall transformed the business from a small specialized player to one of the top five laboratories in the country while setting the industry standard for quality testing. Previously, she led Genzyme Pharmaceuticals and its transformation to an international leader in specialized pharmaceutical ingredient manufacturing.
With a passion for education about the importance of diagnostics in healthcare, Aspinall co-founded the Biomedical Diagnostics program at Arizona State University, the first and only program dedicated to Diagnostics as an independent discipline. ASU awarded their first Master degrees in Diagnostics in 2015 and has 70 students matriculating in Diagnostics this year. A leader in educating payers and policymakers on personalized medicine, she served on the Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in the Obama and Bush administrations.
During the pandemic, Aspinall emerged as a national authority on COVID testing, serving as the Principal Investigator for the ASU grants from The Rockefeller Foundation. With the team at CHS and Decision Theatre, Aspinall helped create TestingCommons.com and EvidenceCommons.com – internationally recognized interactive databases on COVID diagnostics and related research.
Aspinall was named Arizona Biosciences Leader of the Year by the Arizona Biotechnology Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine and one of Women Inc.’s Most Influential Corporate Board Directors. She started her business career at the strategic consulting firm Bain & Company. Aspinall holds an MBA from Harvard Business School and a BA from Tufts University.